[EN] CHROMENE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS<br/>[FR] DERIVES DE CHROMENE A TITRE D'AGENTS ANTI-INFLAMMATOIRES
申请人:PHARMACIA CORP
公开号:WO2004087687A1
公开(公告)日:2004-10-14
The subject invention concerns methods and compounds that have utility in the treatment of a condition associated with cyclooxygenase-2 mediated disorders. Compounds of particular interest are benzopyrans and their analogs defined by formula (I). Wherein Z, X, R1, R2, R3, and R4 are as described in the specification.
Enantioselective Rhodium-Catalyzed Coupling of Arylboronic Acids, 1,3-Enynes, and Imines by Alkenyl-to-Allyl 1,4-Rhodium(I) Migration
作者:Michael Callingham、Benjamin M. Partridge、William Lewis、Hon Wai Lam
DOI:10.1002/anie.201709334
日期:2017.12.18
A chiral rhodiumcomplexcatalyzes the highlyenantioselective coupling of arylboronic acids, 1,3-enynes, and imines to give homoallylic sulfamates. The key step is the generation of allylrhodium(I) species by alkenyl-to-allyl 1,4-rhodium(I) migration. tAm=tert-amyl.
手性铑配合物催化芳基硼酸,1,3-烯炔和亚胺的高度对映选择性偶联,得到均烯丙基氨基磺酸盐。关键步骤是通过烯基至烯丙基1,4-铑(I)的迁移生成烯丙基铑(I)。t Am =叔戊基。
Benzopyran compounds useful for treating inflammatory conditions
申请人:Carter Jeffery
公开号:US20050148777A1
公开(公告)日:2005-07-07
The subject invention concerns methods and compounds that have utility in the treatment of a condition associated with cyclooxygenase-2 mediated disorders. Compounds of particular interest are benzopyrans and their analogs defined by formula 1
Wherein Z, X, R
1
, R 2, R
3
, and R
4
are as described in the specification.
Benzopyran compounds for use in the treatment and prevention of inflammation related conditions
申请人:Carter Jeffery
公开号:US20050148627A1
公开(公告)日:2005-07-07
The subject invention concerns methods and compounds that have utility in the treatment of a condition associated with cyclooxygenase-2 mediated disorders. Compounds of particular interest are benzopyrans and their analogs defined by formula 1
Wherein Z, X, R
1
, R
2
, R
3
, and R
4
are as described in the specification.
Compounds of the formulae, ##STR1## are provided where L is a linking group of the formula, ##STR2## is --Sn(n--C.sub.4 H.sub.9).sub.3 or --Sn(CH.sub.3).sub.3, HgCl or --N.sub.2.sup.+ ; R is hydrogen, methyl, mono-, di- or oligosaccharide; and R' is methyl. The compounds are site-specifically halogenated or radiohalogenated at the A group and coupled with macromolecules such as monoclonal antibodies, peptides or other proteins.